ROCKVILLE, Md., Dec. 9, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation of pre-clinical data for its proprietary DART® molecule, MGD006, at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place in New Orleans. These data demonstrate activity of MGD006, a bispecific molecule that redirects T cells against CD123-positive leukemic cells and results in the clearance of acute myeloid leukemia (AML) blasts in vitro and in vivo.
Help employers find you! Check out all the jobs and post your resume.
